• Logo
  • SBMUJournals

Five-year Survival Rate of Prostate Cancer in Iran: Results of the national cancer-registry system during 2010-2015

Fereshte Aliakbari, Mohammad Ali Ghanbari, Maryam Khayamzadeh, Mohammad Reza Hajian, Farzad Allameh, Mahsa Ahadi, Zahra Sadeghzadeh, Mohammad Esmaeil Akbari, Mohammad Solimani, Shahrzad Nematollah




Background: Prostate Cancer is recognized as the second cause of death due to cancers among men worldwide. Due to the lack of local evidence on the survival rate of patients with prostate cancer, this study aimed to estimate the 5-year survival rate of patients afflicted with this condition in Iran. Materials and Methods:  This study made use of information on 9,772 prostate cancer cases who were registered in the National Cancer Registry during 2010-15. A telephone survey, with a response rate of 35%, was conducted to gather additional information such as death status, demographic characteristics, and clinical profile. Kaplan-Meier estimates was used to estimate five-year survival rates. Results: The overall five-year survival rate of prostate cancer was 82% (95% CI: 80-83%).  Significantly higher five-year survival rates were observed among retired patients (rate: 94%,95%CI: 92-96), patients receiving a combination of radiotherapy and surgery (rate: 92%,95%CI: 89-94), and patients residing in rural areas (rate: 92%, 95%CI: 90-93). Conclusion: We found that various factors such as occupation, area of residence, and the type of medication, may influence on survival rate of prostate cancer. Careful evaluation and understanding of effective factors are required to adopt proper health policies and treatment options. Due to the importance of etiologic and epidemiological data, inclusion of such data into the national registry system for Prostate Cancer is strongly recommended.


Brawley OW. Prostate cancer epidemiology in the United States. World journal of urology. 2012;30(2):195-200.

Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. European urology. 2012;61(6):1079-92.

Grönberg H. Prostate cancer epidemiology. The Lancet. 2003;361(9360):859-64.

Sadjadi A, Nooraie M, Ghorbani A, Alimohammadian M, Zahedi MJ, Darvish-Moghadam S, et al. The incidence of prostate cancer in Iran: results of a population-based cancer registry. Archives of Iranian medicine. 2007;10(4):481-5.

Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. International journal of urology : official journal of the Japanese Urological Association. 2018;25(6):524-31.

Ghiasy S, Abedi AR, Moradi A, Hosseini SY, Karkan MF, Sadri G, et al. Is active surveillance an appropriate approach to manage prostate cancer patients with Gleason Score 3+ 3 who met the criteria for active surveillance? Turkish journal of urology. 2019;45(4):261.

Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Molecular nutrition & food research. 2009;53(2):171-84.

Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11(5):1388-413.

Kimura T, Takahashi H, Okayasu M, Kido M, Inaba H, Kuruma H, et al. Time trends in histological features of latent prostate cancer in Japan. The Journal of urology. 2016;195(5):1415-20.

Zhang L, Yang B-X, Zhang H-T, Wang J-G, Wang H-L, Zhao X-J. Prostate cancer: an emerging threat to the health of aging men in Asia. Asian journal of andrology. 2011;13(4):574.

Pourmand G, Salem S, Mehrsai A, Lotfi M, Amirzargar MA, Mazdak H, et al. The risk factors of prostate cancer: a multicentric case-control study in Iran. Asian Pacific Journal of Cancer Prevention. 2007;8(3):422-8.

Salem S, Hosseini M, Allameh F, Babakoohi S, Mehrsai A, Pourmand G. Serum calcium concentration and prostate cancer risk: a multicenter study. Nutrition and cancer. 2013;65(7):961-8.

Ahmadi H, Allameh F, Baradaran N, Montaser‐Kouhsari L, Bazargan‐Hejazi S, Salem S, et al. Circulating sex hormones play no role in the association between sexual activity and the risk of prostate cancer. The journal of sexual medicine. 2011;8(3):905-13.

Jamali L, Moradi A, Ganji M, Ayati M, Kazeminezhad B, Attar ZF, et al. Potential Prognostic Role for SPOP, DAXX, RARRES1, and LAMP2 as an Autophagy Related Genes in Prostate Cancer. Urology journal. 2019.

Albertsen PC. The prostate cancer conundrum. Oxford University Press; 2003.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA: a cancer journal for clinicians. 2006;56(2):106-30.

Almasi Z, Mohammadian-Hafshejani A, Salehiniya H. Incidence, mortality, and epidemiological aspects of cancers in Iran; differences with the world data. Journal of BU ON. 2016;21(4):994-1004.

Basiri A, Shakhssalim N, Jalaly NY, Miri HH, Partovipour E, Panahi MH. Difference in the incidences of the most prevalent urologic cancers from 2003 to 2009 in Iran. Asian Pac J Cancer Prev. 2014;15(3):1459-63.

Pakzad R, Rafiemanesh H, Ghoncheh M, Sarmad A, Salehiniya H, Hosseini S, et al. Prostate Cancer in Iran: Trends in Incidence and Morphological and Epidemiological Characteristics. Asian Pac J Cancer Prev. 2016;17(2):839-43.

Abedi A-r, Fallah-Karkan M, Allameh F, Ranjbar A, Shadmehr A. Incidental prostate cancer: a 10-year review of a tertiary center, Tehran, Iran. Research and reports in urology. 2018;10:1.

Pourmand G, Allameh F, Mohammad K, Dehghani S, Pourmand B, Mehrsai A, et al. Prostate cancer predicting factors: a preliminary report from Tehran. Urology journal. 2012;9(4):667-72.

Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nature Reviews Cancer. 2002;2(5):389.

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. European urology. 2017;71(4):618-29.

Allameh F, Rahavian AH, Ghiasy S. Prevalence of Castration Success Rate in Iranian Metastatic Prostate Cancer Patients: A Referral Center Statistics. International Journal of Cancer Management. 2018;11(10).

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New England Journal of Medicine. 2016;375(15):1415-24.

Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, et al. Colorectal cancer statistics, 2017. CA: a cancer journal for clinicians. 2017;67(3):177-93.

Kelly SP, Rosenberg PS, Anderson WF, Andreotti G, Younes N, Cleary SD, et al. Trends in the incidence of fatal prostate cancer in the United States by race. European urology. 2017;71(2):195-201.

Tralongo P, Bordonaro S, Di Mari A, Cappuccio F, Giuliano SR. Chemotherapy in frail elderly patients with hormone-refractory prostate cancer: A “real world” experience. Prostate international. 2016;4(1):15-9.

Roach M, Moughan J, Lawton CA, Dicker AP, Zeitzer KL, Gore EM, et al. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. The Lancet Oncology. 2018;19(11):1504-15.

Xu J, Janisse J, Ruterbusch JJ, Ager J, Liu J, Holmes-Rovner M, et al. Patients’ survival expectations with and without their chosen treatment for prostate cancer. The Annals of Family Medicine. 2016;14(3):208-14.

Wendeu-Foyet MG, Bayon V, Cénée S, Trétarre B, Rébillard X, Cancel-Tassin G, et al. Night work and prostate cancer risk: results from the EPICAP Study. Occup Environ Med. 2018;75(8):573-81.

Adler C, Friesen MC, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, et al. Usual adult occupation and risk of prostate cancer in West African men: the Ghana Prostate Study. Occup Environ Med. 2019;76(2):71-7.

Sritharan J, MacLeod J, Harris S, Cole DC, Harris A, Tjepkema M, et al. Prostate cancer surveillance by occupation and industry: the Canadian Census Health and Environment Cohort (CanCHEC). Cancer medicine. 2018;7(4):1468-78.

Morlando M, Pelullo CP, Di Giuseppe G. Prostate cancer screening: Knowledge, attitudes and practices in a sample of men in Italy. A survey. PloS one. 2017;12(10):e0186332.

Froehner M, Koch R, Propping S, Liebeheim D, Hübler M, Baretton GB, et al. Level of education and mortality after radical prostatectomy. Asian journal of andrology. 2017;19(2):173.

Dasgupta P, Baade PD, Aitken JF, Ralph N, Chambers SK, Dunn J. Geographical variations in prostate cancer outcomes: a systematic review of international evidence. Frontiers in oncology. 2019;9:238.

Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: A population‐based cohort study. Cancer. 2009;115(13):2863-71.

Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. Journal of Clinical Oncology. 2011;29(2):235.


  • There are currently no refbacks.